Emilio Cosimo
Overview
Explore the profile of Emilio Cosimo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
179
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vydra J, Cosimo E, Lesny P, Wanless R, Anderson J, Clark A, et al.
Clin Lymphoma Myeloma Leuk
. 2023 Mar;
23(5):e232-e239.
PMID: 36863897
Introduction We report the results of a phase I clinical trial NCT03790072 of an adoptive transfer of γδ T lymphocytes from haploidentical donors in patients with refractory/relapsed acute myeloid leukemia...
2.
Cosimo E, Tarafdar A, Moles M, Holroyd A, Malik N, Catherwood M, et al.
Clin Cancer Res
. 2018 Dec;
25(5):1574-1587.
PMID: 30559170
Purpose: To determine whether inhibition of mTOR kinase-mediated signaling represents a valid therapeutic approach for chronic lymphocytic leukemia (CLL). Experimental Design: Stratification of mTOR activity was carried out in patients...
3.
Nakagawa R, Vukovic M, Tarafdar A, Cosimo E, Dunn K, McCaig A, et al.
Haematologica
. 2015 Jan;
100(4):499-510.
PMID: 25616575
Overwhelming evidence identifies the microenvironment as a critical factor in the development and progression of chronic lymphocytic leukemia, underlining the importance of developing suitable translational models to study the pathogenesis...
4.
Cosimo E, McCaig A, Carter-Brzezinski L, Wheadon H, Leach M, Le Ster K, et al.
Clin Cancer Res
. 2013 Mar;
19(9):2393-405.
PMID: 23532892
Purpose: Chronic lymphocytic leukemia (CLL) is currently incurable with standard chemotherapeutic agents, highlighting the need for novel therapies. Overcoming proliferative and cytoprotective signals generated within the microenvironment of lymphoid organs...
5.
McCaig A, Cosimo E, Leach M, Michie A
PLoS One
. 2012 Nov;
7(11):e48929.
PMID: 23133664
Chemokines and their ligands play a critical role in enabling chronic lymphocytic leukaemia (CLL) cells access to protective microenvironmental niches within tissues, ultimately resulting in chemoresistance and relapse: disruption of...
6.
Nakagawa R, Vukovic M, Cosimo E, Michie A
Eur J Immunol
. 2012 Apr;
42(4):1005-15.
PMID: 22531924
During hematopoietic lineage development, hematopoietic stem cells sequentially commit toward myeloid or lymphoid lineages in a tightly regulated manner, which under normal circumstances is irreversible. However, studies have established that...
7.
McCaig A, Cosimo E, Leach M, Michie A
Br J Haematol
. 2011 Mar;
153(2):199-211.
PMID: 21352196
As antigenic stimulation of the B cell antigen receptor (BCR) is key to chronic lymphocytic leukaemia (CLL) pathogenesis, targeting dysregulated kinases involved in BCR signalling is an attractive therapeutic approach....
8.
Stein T, Cosimo E, Yu X, Smith P, Simon R, Cottrell L, et al.
Am J Pathol
. 2010 Sep;
177(5):2323-33.
PMID: 20847288
Reelin is a secreted, signaling protein associated with neuronal cell positioning and migration. Recently, reelin was found to be epigenetically silenced in gastric and pancreatic cancers in which down-regulation was...
9.
McCluskey A, Boyd M, Ross S, Cosimo E, Clark A, Angerson W, et al.
Clin Cancer Res
. 2005 Nov;
11(21):7929-37.
PMID: 16278418
Purpose: Both [(131)I]meta-iodobenzylguanidine ([(131)I]MIBG) and the topoisomerase I inhibitor topotecan are effective as single-agent treatments of neuroblastoma. The aim of this study was to investigate the efficacy of [(131)I]MIBG in...
10.
Mairs R, Fullerton N, Cosimo E, Boyd M
Nucl Med Biol
. 2005 Oct;
32(7):749-53.
PMID: 16243651
The goal of targeted radionuclide therapy is the deposition in malignant cells of sterilizing doses of radiation without damaging normal tissue. The radiopharmaceutical [(131)I]meta-iodobenzylguanidine ([(131)I]MIBG) is an effective single agent...